BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONC BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

Trading 12-17 13:49:31 EST

308.31

+4.00

+1.31%

High308.97	Low302.00	Vol100.82K
Open305.82	D1 Closing304.31	Amplitude2.29%
Mkt Cap36.69B	Tradable Cap23.32B	Total Shares119.00M
T/O30.86M	T/O Rate0.13%	Tradable Shares75.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":308.305,"timestamp":1765997340584,"preClose":304.31,"halted":0,"volume":100824,"delay":0,"floatShares":75641900,"shares":119000000,"eps":0.584711,"marketStatus":"Trading","change":3.995,"latestTime":"12-17 13:49:31 EST","open":305.82,"high":308.97,"low":302,"amount":30857716.54248,"amplitude":0.022904,"askPrice":308.62,"askSize":8,"bidPrice":307.97,"bidSize":209,"shortable":3,"etf":0,"ttmEps":0.584711,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766005200000},"marketStatusCode":2,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":304.31,"preHourTrading":{"tag":"盘前","latestPrice":305.79,"preClose":304.31,"latestTime":"08:01 EST","volume":85,"amount":25972.46995,"timestamp":1765976484046},"postHourTrading":{"tag":"盘后","latestPrice":304.31,"preClose":304.31,"latestTime":"18:45 EST","volume":2295,"amount":698389.71,"timestamp":1765928714127},"volumeRatio":0.464459,"impliedVol":0.4285,"impliedVolPercentile":0.3859},"requestUrl":"/m/hq/s/ONC/tweets","defaultTab":"tweets","newsList":[{"id":"1174588607","title":"Afternoon Plunge! HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880) Drops 2.77% to Hit New Low, Led by Heavyweights AKESO and BEIGENE","url":"https://stock-news.laohu8.com/highlight/detail?id=1174588607","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174588607?lang=en_us&edition=fundamental","pubTime":"2025-12-15 13:40","pubTimestamp":1765777238,"startTime":"0","endTime":"0","summary":"On the afternoon of December 15, the Hong Kong Stock Connect innovative drug sector accelerated its decline, with the HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880)...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","LU1770034418.SGD","LU0634319403.HKD","BK1583","LU0348735423.USD","LU0348783233.USD","ONC","LU1719994722.HKD","LU0348827113.USD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU2488822045.USD","06160","LU0417516571.SGD","BK1161","LU1961090484.USD","LU2778985437.USD","IE00B543WZ88.USD","LU2476274308.USD","LU2399975544.HKD","520880","BK4139","09926","BK0239","LU0348825331.USD","LU1969619763.USD","LU0307460666.USD","LU2476274720.SGD","688235","IE00BPRC5H50.USD","LU0561508036.HKD","LU1794554557.SGD","LU0417516902.SGD","LU0348767384.USD","LU1303224171.USD","LU2328871848.SGD","LU0348766576.USD","LU1720050803.USD","LU0588546209.SGD","LU1251922891.USD","BK4585","BK1574","BK1500","LU0348784397.USD","BK1588","LU0540923850.HKD"],"gpt_icon":0},{"id":"2590444539","title":"BeOne Medicines' Brukinsa Poised for Growth Through 2026 Despite Rising BTK Competition, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2590444539","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590444539?lang=en_us&edition=fundamental","pubTime":"2025-12-11 00:31","pubTimestamp":1765384283,"startTime":"0","endTime":"0","summary":"BeOne Medicines' (ONC) Brukinsa continues to hold a strong competitive position in the chronic lymphocytic leukemia treatment market, even as new data emerges on competing BTK inhibitor pirtobrutinib,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4526","ONC","MDCO","BK4139","BK4585"],"gpt_icon":0},{"id":"2589090158","title":"BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features","url":"https://stock-news.laohu8.com/highlight/detail?id=2589090158","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589090158?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:03","pubTimestamp":1765148580,"startTime":"0","endTime":"0","summary":"BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical","market":"hk","thumbnail":"/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/25/12/49248671/beone-medicines-announced-sonrotoclax-in-combination-with-brukinsa-demonstrated-rapid-mrd-negativity","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/12/49248671/beone-medicines-announced-sonrotoclax-in-combination-with-brukinsa-demonstrated-rapid-mrd-negativity","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","ONC","LU2463526074.USD","BK4109","ASH","BK4585","MDCO","BK4526"],"gpt_icon":0},{"id":"1102399328","title":"BEIGENE (06160) Grants a Total of 21,300 Restricted Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1102399328","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102399328?lang=en_us&edition=fundamental","pubTime":"2025-12-04 17:00","pubTimestamp":1764838818,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) announced that on November 28, 2025, the Board's Compensation Committee granted a total of 21,300 restricted share units (RSUs) in the form of American Depositary Shares (ADSs) to 147...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1770034418.SGD","LU0307460666.USD","LU0588546209.SGD","LU1969619763.USD","BK4526","BK0239","LU2328871848.SGD","LU1251922891.USD","BK1583","BK4139","06160","ONC","688235","LU1303224171.USD","BK1588","BK1161","LU1719994722.HKD","BK4585","BK1500"],"gpt_icon":0},{"id":"2586574212","title":"Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Key Economic Data Deluge","url":"https://stock-news.laohu8.com/highlight/detail?id=2586574212","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586574212?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:29","pubTimestamp":1764163749,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3% and the actively traded Invesco QQQ Trust (QQQ) was 0.4% higher in Wednesday's premarket activity as investors await a de","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VIS","DE","IYH","FAS","XLY","USO","XLI","SOXX","ONC","SUPV","XLF","IYE","EEM","SPY.AU","IYW","IVV","RTH.AU","SPY","XLE","XLP","RTH","UNG","IYK","SLV","PMR","XRT",".DJI","EETH","VHT.AU","BETH","BITO","IPK","EQR","VHT","UBER","IGM","XLK","FAZ","VDC","EXI","XSD","XLV","IYJ","IGV","IBB"],"gpt_icon":1},{"id":"2586250534","title":"BeOne Medicines (ONC): Assessing Valuation Following Recent Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2586250534","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586250534?lang=en_us&edition=fundamental","pubTime":"2025-11-26 20:37","pubTimestamp":1764160626,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) has been getting attention for its recent stock performance, with shares showing noticeable movement over the past month. Investors are keeping an eye on how the company’s sustained gains might reflect its current direction.\nSee our latest analysis for BeOne Medicines.\nThe stock’s 6.3% share price return over the past month signals growing momentum and builds on the impressive 82% year-to-date gain. While short-term pullbacks have occurred, BeOne Medicines stands out due...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-assessing-valuation-following-recent-sha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-assessing-valuation-following-recent-sha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4526","BK4585","ONC","MDCO","BK4139"],"gpt_icon":0},{"id":"2586725679","title":"BeOne Medicines Lymphoma Drug Gets FDA Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2586725679","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586725679?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:21","pubTimestamp":1764156060,"startTime":"0","endTime":"0","summary":"BeOne Medicines said U.S. regulators have agreed to fast-track the review its new drug to treat adults with mantle cell lymphoma, a form of blood cancer.The cancer treatment company said Wednesday that the Food and Drug Administration has accepted and granted priority review to a new drug application for sonrotoclax, a new BCL2 inhibitor intended to treat adult patients with relapsed or refractory mantle cell lymphoma.Mantle cell lymphoma is a rare, fast-growing blood cancer that starts in the lymph nodes.The decision was based on data from a phase 1/2 study which enrolled 125 adult patients with the specific type of blood cancer who had received prior treatment. The trial results found that sonorotoclax achieved its primary endpoints of overall response rate, and also showed promising results across several secondary efficacy endpoints, it said.\"Sonrotoclax is advancing with remarkable speed, from breakthrough therapy designation to priority review, all within a short window,\" Global ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","BK4139","BK4585","BK4526","MDCO"],"gpt_icon":0},{"id":"2586256118","title":"BeOne Medicines says FDA grants Priority Review to NDA for sonrotoclax","url":"https://stock-news.laohu8.com/highlight/detail?id=2586256118","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586256118?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:05","pubTimestamp":1764155134,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. FDA has accepted and granted Priority Review to a New Drug Application for sonrotoclax, a next-genera...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-says-fda-grants-priority-review-to-nda-for-sonrotoclax-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-says-fda-grants-priority-review-to-nda-for-sonrotoclax-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","BK4526","BK4139","MDCO","BK4585"],"gpt_icon":0},{"id":"2586476871","title":"Jefferies Sticks to Its Buy Rating for BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586476871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586476871?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:36","pubTimestamp":1764077793,"startTime":"0","endTime":"0","summary":"In a report released today, Clara Dong from Jefferies maintained a Buy rating on BeOne Medicines, with a price target of $420.00. According to TipR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","MDCO"],"gpt_icon":0},{"id":"2586427711","title":"BeOne Medicines (ONC) Is Up After ZIIHERA Phase 3 Trial Shows Strong Efficacy for HER2-Positive Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2586427711","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586427711?lang=en_us&edition=fundamental","pubTime":"2025-11-25 19:22","pubTimestamp":1764069734,"startTime":"0","endTime":"0","summary":"In November 2025, BeOne Medicines Ltd. announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial, showing that ZIIHERA (zanidatamab) in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA, led to highly statistically significant improvements in progression-free and overall survival for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.\nThe study’s results highlight both clinically meaningful efficacy benefits and a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-is-up-after-ziihera-phase-3-trial-shows","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-is-up-after-ziihera-phase-3-trial-shows","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONC","BK4139","MDCO","BK4526","BK4585"],"gpt_icon":0},{"id":"2586049123","title":"BeOne Medicines Initiated at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2586049123","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586049123?lang=en_us&edition=fundamental","pubTime":"2025-11-25 02:01","pubTimestamp":1764007260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 13:01 ET (18:01 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","BK4526","BK4139","BK4585","MDCO"],"gpt_icon":0},{"id":"2585944464","title":"BeOne Medicines initiated with a Buy at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2585944464","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585944464?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:35","pubTimestamp":1763987752,"startTime":"0","endTime":"0","summary":"Truist initiated coverage of BeOne Medicines (ONC) with a Buy rating and $400 price target The firm expect Brukinsa’s revenue stream to sustainably...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-initiated-with-a-buy-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-initiated-with-a-buy-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","ONC","MDCO","BK4526"],"gpt_icon":0},{"id":"2585645844","title":"Beone Medicines : Truist Securities Initiates Coverage With Buy Rating; Target Price $400","url":"https://stock-news.laohu8.com/highlight/detail?id=2585645844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585645844?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:35","pubTimestamp":1763987717,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3X00GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONC","BK4585","688235","BK4526","BK0239","BK4139"],"gpt_icon":0},{"id":"1111797116","title":"BEIGENE Opens Over 3% Higher in Early Trading; CSCI Maintains \"Buy\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1111797116","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111797116?lang=en_us&edition=fundamental","pubTime":"2025-11-18 09:40","pubTimestamp":1763430018,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) opened more than 3% higher in early trading. At the time of writing, the stock was up 3.53% to HK$223.2, with a turnover of HK$11.96 million. On November 17, BEIGENE announced...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK0239","BK4139","LU0588546209.SGD","LU1251922891.USD","BK1583","688235","BK1161","ONC","LU1303224171.USD","LU1969619763.USD","LU0307460666.USD","BK1588","LU1770034418.SGD","LU1719994722.HKD","06160","LU2328871848.SGD","BK1500","BK4526"],"gpt_icon":1},{"id":"1104425713","title":"HK Stock Movement | BEIGENE (06160) Opens Over 3% Higher as Phase 3 Clinical Study of Zanidatamab Combined with Tislelizumab and Chemotherapy Shows Positive Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1104425713","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104425713?lang=en_us&edition=fundamental","pubTime":"2025-11-18 09:28","pubTimestamp":1763429302,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) opened over 3% higher, rising 3.53% to HK$223.2 by the time of reporting, with a trading volume of HK$11.96 million. On November 17, BEIGENE announced positive results from the Phase...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","LU1251922891.USD","LU2328871848.SGD","BK1161","LU1719994722.HKD","BK0239","06160","LU1969619763.USD","LU0307460666.USD","BK4585","BK4139","LU0588546209.SGD","BK1588","ONC","LU1770034418.SGD","BK1500","LU1303224171.USD","688235","BK1583"],"gpt_icon":1},{"id":"1192429928","title":"BEIGENE (06160) Grants 16,500 Restricted Share Units in the Form of ADS","url":"https://stock-news.laohu8.com/highlight/detail?id=1192429928","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192429928?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:22","pubTimestamp":1763130133,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) announced that on November 10, 2025, the Board's Compensation Committee granted a total of 16,500 restricted share units in the form of American Depositary Shares (ADS) to 143...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1719994722.HKD","LU2328871848.SGD","BK1161","BK1588","LU1303224171.USD","LU0307460666.USD","BK4585","LU1770034418.SGD","BK1583","688235","BK4139","BK4526","BK1500","ONC","BK0239","06160","LU1969619763.USD","LU0588546209.SGD","LU1251922891.USD"],"gpt_icon":0},{"id":"1142755606","title":"Stock Track | BeiGene Shares Soar 5.03% Following Strong Q3 Financial Results and Turnaround to Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=1142755606","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142755606?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:56","pubTimestamp":1762959402,"startTime":"0","endTime":"0","summary":"BeiGene Ltd. (ONC) saw its stock price surge 5.03% in pre-market trading on Wednesday, following the release of its impressive third-quarter financial results for 2025. The biotechnology company's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ONC"],"gpt_icon":0},{"id":"1198959086","title":"Beigene (688235.SH) Reports Q1-Q3 Results: Net Profit Attributable to Shareholders at RMB1.139 Billion, Turning Loss into Profit YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=1198959086","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198959086?lang=en_us&edition=fundamental","pubTime":"2025-11-12 18:00","pubTimestamp":1762941644,"startTime":"0","endTime":"0","summary":"Beigene (688235.SH) disclosed its Q3 2025 financial report, showing revenue of RMB27.595 billion for the first three quarters, a year-on-year increase of 44.2%. Net profit attributable to...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1251922891.USD","LU1719994722.HKD","LU0588546209.SGD","BK4526","LU1303224171.USD","BK1583","BK1161","ONC","BK4585","06160","LU0307460666.USD","LU1969619763.USD","BK1588","LU1770034418.SGD","LU2328871848.SGD","688235","BK1500","BK0239","BK4139"],"gpt_icon":0},{"id":"1124862178","title":"BEIGENE Surges Over 6% in Early Trading as Zanubrutinib Exceeds Expectations in US and European Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=1124862178","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124862178?lang=en_us&edition=fundamental","pubTime":"2025-11-12 10:10","pubTimestamp":1762913423,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) saw its shares rise by 6.08% in early trading, reaching HK$209.40, with a trading volume of HK$725 million. The company recently reported its financial results, with Q3 revenue...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","LU1969619763.USD","BK1500","LU1770034418.SGD","BK4585","BK1588","06160","LU1303224171.USD","BK1583","BK4526","BK0239","BK4139","ONC","BK1161","LU0307460666.USD","688235","LU1251922891.USD","LU1719994722.HKD","LU2328871848.SGD"],"gpt_icon":0},{"id":"1147279578","title":"BEIGENE (06160) Zanubrutinib Sales in US and Europe Exceed Expectations; Haitong International Maintains \"Outperform\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1147279578","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147279578?lang=en_us&edition=fundamental","pubTime":"2025-11-11 14:34","pubTimestamp":1762842851,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) has seen stronger-than-expected sales growth of its Zanubrutinib in the US and European markets, prompting Haitong International to raise its revenue forecasts for 2025–2027 to $5.3...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1251922891.USD","BK0239","LU1303224171.USD","BK4526","LU1719994722.HKD","LU1770034418.SGD","LU0307460666.USD","BK1588","BK1500","LU2328871848.SGD","ONC","688235","BK4585","BK1161","06160","BK4139","LU0588546209.SGD","LU1969619763.USD","BK1583"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":-0.0451},{"period":"1month","weight":-0.1681},{"period":"3month","weight":-0.084},{"period":"6month","weight":0.2039},{"period":"1year","weight":0.7258},{"period":"ytd","weight":0.6475}],"compareEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":0.0103},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.1363},{"period":"1year","weight":0.1188},{"period":"ytd","weight":0.1583}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.079635},{"month":2,"riseRate":0.666667,"avgChangeRate":0.038229},{"month":3,"riseRate":0.4,"avgChangeRate":-0.025903},{"month":4,"riseRate":0.4,"avgChangeRate":0.021288},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019094},{"month":6,"riseRate":0.5,"avgChangeRate":0.012468},{"month":7,"riseRate":0.8,"avgChangeRate":0.147208},{"month":8,"riseRate":0.6,"avgChangeRate":0.034201},{"month":9,"riseRate":0.6,"avgChangeRate":0.069537},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004517},{"month":11,"riseRate":0.6,"avgChangeRate":0.063715},{"month":12,"riseRate":0.3,"avgChangeRate":-0.043516}],"exchange":"NASDAQ","name":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS,ONC,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎国际,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股价,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股市,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票价格,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票交易,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票购买,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction